This systematic review catalogues 112 neonatal and pediatric vancomycin population pharmacokinetic models and introduces an expert-derived scoring framework to help TDM pharmacists select fit-for-purpose models for model-informed precision dosing.
Optimize vancomycin dosing with precision models in young patients.
Vancomycin dosing in neonates and children is challenging due to variability in pharmacokinetics, making precision dosing crucial for efficacy and safety. Among 112 models identified, the study highlights the Chen (2023) model as the best for neonatal and pediatric populations based on comprehensive evaluation. The review provides a standardized tool for selecting appropriate pharmacokinetic models, enhancing model-informed precision dosing for vancomycin in young patients. The Chen (2023) popPK model is recommended for vancomycin precision dosing in neonates and children.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Authors:Vander Elst Z, Spiessens PJ, Vanneste D, Dia N, Gijsen M, Spriet I, Allegaert K, Dreesen E, Smits A
Citation:Vander Elst Z, Spiessens PJ, Vanneste D, et al. Systematic review and scoring-based selection of pharmacokinetic models for precision dosing of vancomycin in neonates and children. British journal of clinical pharmacology. 2026;92(7):2028-2048. doi:10.1002/bcp.70530
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.